Published:
The New England Journal of Medicine
Date:
Abstract:
Type 2 diabetes mellitus is the leading cause of kidney failure worldwide,
but few effective long-term treatments are available. In cardiovascular
trials of inhibitors of sodium-glucose cotransporter 2 (SGLT2), exploratory
results have suggested that such drugs may improve renal outcomes in
patients with type 2 diabetes.